Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RenovoRx (RNXT) Cash & Equivalents (2024 - 2025)

RenovoRx's Cash & Equivalents history spans 2 years, with the latest figure at $10.0 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 4.57% year-over-year to $10.0 million; the TTM value through Sep 2025 reached $10.0 million, up 4.57%, while the annual FY2024 figure was $7.0 million, N/A changed from the prior year.
  • Cash & Equivalents for Q3 2025 was $10.0 million at RenovoRx, down from $12.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $14.4 million in Q1 2025 and bottomed at $4.4 million in Q1 2024.